NYSE:ABBVBiotechs
AbbVie Pricing Pact And Cancer Trial Data Reframe Long Term Outlook
AbbVie (NYSE:ABBV) has agreed a three year deal with the Trump administration to cut US drug prices and invest $100b in US based R&D, manufacturing, and patient access.
The company also reported positive topline Phase 3 results for its bispecific antibody epcoritamab in relapsed or refractory diffuse large B cell lymphoma, with improved progression free survival and response rates.
AbbVie enters this news cycle with a current share price of $223.93 and a value score of 5 on Simply Wall St,...